ScienceDex / Researcher record
Xiangpeng Kong
- NYU Grossman School of Medicine · Biochemistry (NIH department code)
From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.
- R01 Holder
- Early Career
NIH Funding · FY2026
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $859,597 | 1 | #17,727 |
| 2025 | $824,847 | 1 | #19,656 |
| 2026 | $857,511 | 1 | #21,538 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20241 record
- FY20251 record
- FY2026 · selected1 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 2264145Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award categories
- Biochemistry
FY2026 award records by amount
NIH award records listing Xiangpeng Kong as a PI. Multi-PI records show the full award amount for context.
- 5R01AI181676-03R01Contact PIEliciting Broadly Neutralizing Antibody Responses against HIV-1 Fusion Peptide Epitope by AB Toxin B Subunit-Based ImmunogensNYU Grossman School of Medicine · Biochemistry (NIH department code)$857.5Kaward amount
Award organization
Organizations that administered FY2026 awards listing Xiangpeng Kong as a PI.
FY2026 award administered by NYU Grossman School of Medicine (NY).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardNYU Grossman School of Medicine
- 2024$500K Cumulative Funding
- 2025$1M Cumulative Funding
- 2025R01 Grant Holder
- 2026$2M Cumulative Funding